ImmunoVec Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $12.7M

  • Investors
  • 8

ImmunoVec General Information

Description

Developer of in vivo cell engineering technology designed to precisely engineer targeted cell types within the human body through cell-type-specific gene expression. The company offers synthetic promoters, expression cassettes, viral and non-viral delivery systems, and polymeric and lipid nanoparticles, enabling researchers and biopharmaceutical companies to engineer targeted gene expression in specific cell types.

Contact Information

Formerly Known As
Rarity Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 23110 Mariposa De Oro
  • Malibu, CA 90265
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 23110 Mariposa De Oro
  • Malibu, CA 90265
  • United States

ImmunoVec Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoVec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 14-Jul-2026 $12.7M Completed Startup
4. Grant 08-Oct-2025 Completed Startup
3. Grant 04-Aug-2023 Completed Stealth
2. Seed Round 02-Mar-2022 $4.3M $4.3M Completed Stealth
1. Accelerator/Incubator Completed Stealth
To view ImmunoVec’s complete valuation and funding history, request access »

ImmunoVec Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view ImmunoVec’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ImmunoVec Patents

ImmunoVec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240287546-A1 Enhancers and vectors Pending 16-Jun-2022
AU-2023290161-A1 Improved enhancers and vectors Pending 16-Jun-2022
EP-4540396-A1 Improved enhancers and vectors Pending 16-Jun-2022
EP-4540396-A4 Improved enhancers and vectors Pending 16-Jun-2022
WO-2023244737-A1 Improved enhancers and vectors Inactive 16-Jun-2022 C12N15/86
To view ImmunoVec’s complete patent history, request access »

ImmunoVec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoVec Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Black Diamond Ventures Venture Capital Minority
ARPA-H Government
California Institute for Regenerative Medicine Government
Anthem Venture Partners Venture Capital Minority
Constellar Ventures Family Office Minority
You’re viewing 5 of 8 investors. Get the full list »

ImmunoVec FAQs

  • When was ImmunoVec founded?

    ImmunoVec was founded in 2019.

  • Where is ImmunoVec headquartered?

    ImmunoVec is headquartered in Malibu, CA.

  • What is the size of ImmunoVec?

    ImmunoVec has 9 total employees.

  • What industry is ImmunoVec in?

    ImmunoVec’s primary industry is Biotechnology.

  • Is ImmunoVec a private or public company?

    ImmunoVec is a Private company.

  • What is the current valuation of ImmunoVec?

    The current valuation of ImmunoVec is .

  • What is ImmunoVec’s current revenue?

    The current revenue for ImmunoVec is .

  • How much funding has ImmunoVec raised over time?

    ImmunoVec has raised $17M.

  • Who are ImmunoVec’s investors?

    Black Diamond Ventures, ARPA-H, California Institute for Regenerative Medicine, Anthem Venture Partners, and Constellar Ventures are 5 of 8 investors who have invested in ImmunoVec.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process